Biotech IV Monitor

MIRM — Mirum Pharmaceuticals Inc.

$6.9B market cap · 6 upcoming readouts tracked

Clinical trial readout dates for Mirum Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts63 Phase 3
Market cap$6.9B
Cash & investments$670M~16 quarters at last loss rate
Recent 8-K filings3latest 2026-11-10

Upcoming readouts

Phase 2 Volixibat
Primary Biliary Cholangitis; PBC · NCT05050136
January 2027
Ongoing
Phase 3 Brelovitug 300 mg
Chronic Hepatitis D Infection · NCT07200908
June 2027
Recruiting
Phase 2/3 Brelovitug (BJT-778)
Chronic Hepatitis D · NCT07454837
August 2027
Recruiting
Phase 2 Low dose of MRM-3379
Fragile X Syndrome · NCT07209462
October 2027
Recruiting
Phase 2 Maralixibat
Intrahepatic Cholestasis of Pregnancy · NCT07823127
January 2029
Not Yet Recruiting
Phase 2/3 Brelovitug 300 mg
Chronic Hepatitis D Infection · NCT06907290
May 2029
Ongoing

Cash position

Mirum Pharmaceuticals Inc. reported $670M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $41M; at that rate the cash would last about 16 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-10
8-K Results of Operations — earnings, may carry pipeline updates2026-11-03
8-K Other Events — often topline trial data2026-10-26

Companies working on similar indications

Discussion

No messages yet. If you follow MIRM, you can start the conversation.
Track MIRM in real time
See live implied volatility for MIRM and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on MIRM
Contact — questions or corrections about MIRM: dukeupt@gmail.com